Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Yu Mi Kang, M.D.

Concepts (190)

Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Yu Mi Kang's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Yu Mi Kang has written about over time.
Republic of Korea, 12 publications between 2012 and 2021, average publication date June 2016. Cerebrovascular Disorders, 1 publications between 2016 and 2016, average publication date September 2016. Obesity, 4 publications between 2014 and 2019, average publication date December 2016. Diabetes Mellitus, Type 2, 14 publications between 2009 and 2024, average publication date December 2016. Fatty Liver, 3 publications between 2016 and 2017, average publication date January 2017. Intra-Abdominal Fat, 1 publications between 2017 and 2017, average publication date June 2017. Life Expectancy, 1 publications between 2017 and 2017, average publication date August 2017. Hypoglycemic Agents, 5 publications between 2016 and 2019, average publication date July 2018. Glucagon-Like Peptides, 1 publications between 2018 and 2018, average publication date December 2018. Cardiovascular Diseases, 5 publications between 2016 and 2024, average publication date April 2019. Dipeptidyl-Peptidase IV Inhibitors, 1 publications between 2019 and 2019, average publication date June 2019. Metformin, 1 publications between 2019 and 2019, average publication date June 2019. Sulfonylurea Compounds, 1 publications between 2019 and 2019, average publication date June 2019.

To see the data from this visualization as text, click here.
Kang's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (190)
Explore
_
Co-Authors (8)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.